ethoxyresorufin has been researched along with Benign Neoplasms in 1 studies
ethoxyresorufin: structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data indicate that cancer patients treated with DTIC who possess any of the CYP1A1-T461N and I462V variants or the CYP1A2-F186L, D348N, I386F, R431W, and R456H variants are likely to have decreased prodrug activation, and hence may respond less favorably to DTIC treatment compared with individuals with wild-type CYP1A alleles." | 1.43 | Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy. ( Korprasertthaworn, P; Lewis, BC; Miners, JO, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, BC | 1 |
| Korprasertthaworn, P | 1 |
| Miners, JO | 1 |
1 other study available for ethoxyresorufin and Benign Neoplasms
| Article | Year |
|---|---|
Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.
Topics: Antineoplastic Agents, Alkylating; Catalysis; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Daca | 2016 |